Class information for: |
Basic class information |
| Class id | #P | Avg. number of references |
Database coverage of references |
|---|---|---|---|
| 35959 | 89 | 41.6 | 82% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
| 328 | 3 | PHOSPHOLIPASE D//STIM1//REGUCALCIN | 38118 |
| 1764 | 2 | STIM1//ORAI1//STORE OPERATED CALCIUM ENTRY | 6417 |
| 35959 | 1 | CARBOXYAMIDOTRIAZOLE//PROOFREADING STIMULATION//EQUIMOLAR COMBINATIONS OF NUCLEOTIDES PRECURSORS | 89 |
Terms with highest relevance score |
| rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|---|
| 1 | CARBOXYAMIDOTRIAZOLE | authKW | 3528996 | 13% | 86% | 12 |
| 2 | PROOFREADING STIMULATION | authKW | 1029292 | 3% | 100% | 3 |
| 3 | EQUIMOLAR COMBINATIONS OF NUCLEOTIDES PRECURSORS | authKW | 686194 | 2% | 100% | 2 |
| 4 | L651582 | authKW | 686194 | 2% | 100% | 2 |
| 5 | NEW ADJUVANT CANCER THERAPY | authKW | 686194 | 2% | 100% | 2 |
| 6 | AMINOIMDAZOLECARBOXYAMIDE AICA | authKW | 343097 | 1% | 100% | 1 |
| 7 | BECKMAN MACULA OPHTHALMOL | address | 343097 | 1% | 100% | 1 |
| 8 | CARBOXAMIDOIMIDAZOLES CAIS | authKW | 343097 | 1% | 100% | 1 |
| 9 | CARBOXYAMIDO TRIAZOLE CAI | authKW | 343097 | 1% | 100% | 1 |
| 10 | CARBOXYAMIDO TRIAZOLE PHARMACOKINETICS | authKW | 343097 | 1% | 100% | 1 |
Web of Science journal categories |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | Oncology | 598 | 43% | 0% | 38 |
| 2 | Pharmacology & Pharmacy | 48 | 16% | 0% | 14 |
| 3 | Ophthalmology | 18 | 4% | 0% | 4 |
| 4 | Cell Biology | 12 | 8% | 0% | 7 |
| 5 | Biochemistry & Molecular Biology | 10 | 13% | 0% | 12 |
| 6 | Mathematical & Computational Biology | 10 | 2% | 0% | 2 |
| 7 | Biology | 8 | 3% | 0% | 3 |
| 8 | Hematology | 6 | 3% | 0% | 3 |
| 9 | Integrative & Complementary Medicine | 6 | 1% | 0% | 1 |
| 10 | Virology | 5 | 2% | 0% | 2 |
Address terms |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | BECKMAN MACULA OPHTHALMOL | 343097 | 1% | 100% | 1 |
| 2 | COMPLEX SYST MOL BIOL MED SYBIOM | 343097 | 1% | 100% | 1 |
| 3 | MED OVARIAN CANC CLIN | 343097 | 1% | 100% | 1 |
| 4 | PATHO 1 | 343097 | 1% | 100% | 1 |
| 5 | PRIMARY CARE STAT | 343097 | 1% | 100% | 1 |
| 6 | REHAB RD COE | 343097 | 1% | 100% | 1 |
| 7 | DYNAM ORG GENOME | 171548 | 1% | 50% | 1 |
| 8 | SCI BOARD | 152481 | 4% | 11% | 4 |
| 9 | MOL SIGNALING SECT | 100057 | 8% | 4% | 7 |
| 10 | SEZIONE BIOL GENET | 42885 | 1% | 13% | 1 |
Journals |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | BULLETIN DE L INSTITUT PASTEUR | 4632 | 2% | 1% | 2 |
| 2 | CURRENT SIGNAL TRANSDUCTION THERAPY | 1579 | 1% | 0% | 1 |
| 3 | CLINICAL CANCER RESEARCH | 1129 | 8% | 0% | 7 |
| 4 | CANCER AND METASTASIS REVIEWS | 1125 | 2% | 0% | 2 |
| 5 | INVESTIGATIONAL NEW DRUGS | 535 | 2% | 0% | 2 |
| 6 | MONATSHEFTE FUR CHEMIE | 499 | 3% | 0% | 3 |
| 7 | JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS | 465 | 1% | 0% | 1 |
| 8 | GROWTH FACTORS | 430 | 1% | 0% | 1 |
| 9 | JOURNAL OF CLINICAL ONCOLOGY | 334 | 4% | 0% | 4 |
| 10 | LUNG CANCER | 307 | 2% | 0% | 2 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
| Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
|---|---|---|---|---|
| 1 | AZAD, N , PERROY, A , GARDNER, E , IMAMURA, CK , GRAVES, C , SAROSY, GA , MINASIAN, L , KOTZ, H , RAGGIO, M , FIGG, WD , ET AL (2009) A PHASE I STUDY OF PACLITAXEL AND CONTINUOUS DAILY CAI IN PATIENTS WITH REFRACTORY SOLID TUMORS.CANCER BIOLOGY & THERAPY. VOL. 8. ISSUE 19. P. 1800 -1805 | 20 | 77% | 5 |
| 2 | HUSSAIN, MM , KOTZ, H , MINASIAN, L , PREMKUMAR, A , SAROSY, G , REED, E , ZHAI, SP , STEINBERG, SM , RAGGIO, M , OLIVER, VK , ET AL (2003) PHASE II TRIAL OF CARBOXYAMIDOTRIAZOLE IN PATIENTS WITH RELAPSED EPITHELIAL OVARIAN CANCER.JOURNAL OF CLINICAL ONCOLOGY. VOL. 21. ISSUE 23. P. 4356-4363 | 21 | 58% | 44 |
| 3 | JOHNSON, EA , MARKS, RS , MANDREKAR, SJ , HILLMAN, SL , HAUGE, MD , BAUMAN, MD , WOS, EJ , MOORE, DF , KUGLER, JW , WINDSCHITL, HE , ET AL (2008) PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF MAINTENANCE CAI OR PLACEBO IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AFTER COMPLETION OF INITIAL THERAPY (NCCTG 97-24-51).LUNG CANCER. VOL. 60. ISSUE 2. P. 200-207 | 12 | 75% | 34 |
| 4 | BAUER, KS , FIGG, WD , HAMILTON, JM , JONES, EC , PREMKUMAR, A , STEINBERG, SM , DYER, V , LINEHAN, WM , PLUDA, JM , REED, E , (1999) A PHARMACOKINETICALLY GUIDED PHASE II STUDY OF CARBOXYAMIDO-TRIAZOLE IN ANDROGEN-INDEPENDENT PROSTATE CANCER.CLINICAL CANCER RESEARCH. VOL. 5. ISSUE 9. P. 2324-2329 | 11 | 100% | 38 |
| 5 | BERLIN, J , TUTSCH, KD , ARZOOMANIAN, RZ , ALBERTI, D , BINGER, K , FEIERABEND, C , DRESEN, A , MARNOCHA, RA , PLUDA, J , WILDING, G , (2002) PHASE I AND PHARMACOKINETIC STUDY OF A MICRONIZED FORMULATION OF CARBOXYAMIDOTRIAZOLE, A CALCIUM SIGNAL TRANSDUCTION INHIBITOR: TOXICITY, BIOAVAILABILITY AND THE EFFECT OF FOOD.CLINICAL CANCER RESEARCH. VOL. 8. ISSUE 1. P. 86-94 | 12 | 80% | 17 |
| 6 | YANG, JL , QU, XJ , YU, Y , KOHN, EC , FRIEDLANDER, ML , (2008) SELECTIVE SENSITIVITY TO CARBOXYAMIDOTRIAZOLE BY HUMAN TUMOR CELL LINES WITH DNA MISMATCH REPAIR DEFICIENCY.INTERNATIONAL JOURNAL OF CANCER. VOL. 123. ISSUE 2. P. 258-263 | 16 | 48% | 6 |
| 7 | GUO, L , YE, CY , CHEN, WY , YE, H , ZHENG, R , LI, J , YANG, HF , YU, XL , ZHANG, DC , (2008) ANTI-INFLAMMATORY AND ANALGESIC POTENCY OF CARBOXYAMIDOTRIAZOLE, A TUMOROSTATIC AGENT.JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. VOL. 325. ISSUE 1. P. 10 -16 | 15 | 48% | 8 |
| 8 | PERABO, FGE , DEMANT, AW , WIRGER, A , SCHMIDT, DH , SITIA, M , WARDELMANN, E , MULLER, SC , KOHN, EC , (2005) CARBOXYAMIDO-TRIAZOLE (CAI) REVERSES THE BALANCE BETWEEN PROLIFERATION AND APOPTOSIS IN A RAT BLADDER CANCER MODEL.ANTICANCER RESEARCH. VOL. 25. ISSUE 2A. P. 725-729 | 12 | 67% | 2 |
| 9 | JU, R , WU, DW , GUO, L , LI, J , YE, CY , ZHANG, DC , (2012) INHIBITION OF PRO-INFLAMMATORY CYTOKINES IN TUMOUR ASSOCIATED MACROPHAGES IS A POTENTIAL ANTI-CANCER MECHANISM OF CARBOXYAMIDOTRIAZOLE.EUROPEAN JOURNAL OF CANCER. VOL. 48. ISSUE 7. P. 1085 -1095 | 17 | 36% | 3 |
| 10 | BAUER, KS , KOHN, EC , LUSH, RM , STEINBERG, SM , DAVIS, P , KOHLER, D , REED, E , FIGG, WD , (1998) PHARMACOKINETICS AND RELATIVE BIOAVAILABILITY OF CARBOXYAMIDO-TRIAZOLE WITH RESPECT TO FOOD AND TIME OF ADMINISTRATION: USE OF A SINGLE MODEL FOR SIMULTANEOUS DETERMINATION OF CHANGING PARAMETERS.JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS. VOL. 26. ISSUE 6. P. 673 -687 | 10 | 91% | 4 |
Classes with closest relation at Level 1 |